Webdisclosure.com

Search

HARDMAN & CO RESEARCH Hardman & Co Research: Diurnal (DNL): . and more to come (news flow)

Directive transparence : information réglementée

28/02/2020 08:30

Hardman & Co Research
Hardman & Co Research: Diurnal (DNL): . and more to come (news flow)

28-Feb-2020 / 07:30 GMT/BST


Hardman & Co Research: . and more to come (news flow)

Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term 'Adrenal Franchise'. Its first drug, Alkindi, is being rolled out through key European markets, and sales exceeded £1.1m in 1H'20. Despite unexpected Phase III trial results, positive feedback from the EMA has opened a pathway for regulatory submission of Chronocort for adult CAH and AI in Europe. Discussions with potential US partners for both products are also expected to crystallise in the first half of calendar 2020.

Please click on the link below for the full report:

https://www.hardmanandco.com/research/corporate-research/and-more-to-come-news-flow/

If you are interested in meeting the company, you can register your interest by clicking on the above link.

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Martin Hall


+44 20 7194 7632

 

mh@hardmanandco.com
 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

985661  28-Feb-2020 

fncls.ssp?fn=show_t_gif&application_id=985661&application_name=news&site_id=symex